Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143131 | 0.82 | ATM (0.44) | ATMDPP4DPP8DPP9 | |
| SCHEMBL1048496 | 0.81 | DPP4 (0.35) | DPP4 | |
| SCHEMBL1362536 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9 | |
| SCHEMBL28455113 | 0.78 | PLA2G1B (0.30) | — | |
| SCHEMBL28763852 | 0.77 | DPP4 (0.38) | DPP4DPP8DPP9 | |
| SCHEMBL29163837 | 0.74 | UCHL1 (0.31) | ATM | |
| SCHEMBL1923044 | 0.74 | MMP2 (0.42) | MMP2ANPEPATM | |
| SCHEMBL10002327 | 0.74 | MMP2 (0.42) | MMP2ANPEPATM | |
| SCHEMBL21110991 | 0.74 | MMP2 (0.42) | MMP2ANPEPATM | |
| SCHEMBL17842674 | 0.74 | MMP2 (0.42) | MMP2ANPEPATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362145-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115362145-A | Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3204379-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | Genentech, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9708296-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2925745-A1 | CXCR7 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2014164558-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MMP2 2621/4885ANPEP 3415/4885ATM 1579/4885 |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | SIRT1, SIRT3, SIRT5 | MMP2 2556/4885ANPEP 1017/4885ATM 4811/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | MMP2 3811/4885ANPEP 2530/4885ATM 989/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | MMP2 652/4885ANPEP 1030/4885ATM 718/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | MMP2 876/4885ANPEP 4062/4885ATM 973/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | MMP2 3811/4885ANPEP 2530/4885ATM 989/4885 |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | MMP2 2496/4885ANPEP 2396/4885ATM 3844/4885 |
| US-20130303509-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MMP2 856/4885ANPEP 819/4885ATM 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.